An observational study in Advanced Lung Cancer and Sarcopenia, sponsored by Prince of Songkla University. Recruiting at 1 site in Thailand. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-22.
Sponsored by Prince of Songkla University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Sarcopenia with a site in Thailand — 6 open to participants now, 6 under way, 1 of them phase 3. Sarcopenia · Thailand.
Among the 12 studies in Sarcopenia with a site in Thailand, this one is the only one that started in 2022, is one of 4 observational ones, and was the 8th registered.
1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.
Browse Sarcopenia studies →6 of the 12 studies in Sarcopenia with a site in Thailand are open now. Recruiting first, the newest first:
Chulalongkorn University · Sites in Thailand
Ages 65+
Mahidol University · Sites in Thailand
Ages 18–75
Mahidol University · Sites in Thailand
Ages 18–85
Abbott Nutrition · Sites in Thailand
Ages 55–99
Siriraj Hospital · Sites in Thailand
Ages 60–90
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2015; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 120 across 455 observational studies indexed under Sarcopenia.
Median enrollment 65 across the 8 interventional studies, 202 across the 4 observational. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 7 most frequent:
Prince of Songkla University is the lead sponsor of 116 studies on the registry; 13 are open to participants now.
Prince of Songkla University has 1 study filed under Sarcopenia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Sarcopenia with a site in Thailand, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Lung cancer is a common disease leading to 18 % of cancer deaths worldwide. Despite various improvement in treatment, there still remains low 5-year survival rate of 10-20 % in advanced lung cancer patients. Skeletal muscle mass and physical performance have been shown to effect overall survival and prognosis in lung cancer. This research focuses on effects of different treatment of lung cancer such as chemotherapy, targeted therapy and immunotherapy on skeletal muscle mass and physical performance.
Lung cancer is a common disease leading to 18% of all cancer deaths worldwide. Prognosis of lung cancer depends on various factors like disease stage, socioeconomic factors, body composition factors such as sarcopenia have been shown to be associated with poor prognosis and survival. Sarcopenia is defined as decline in muscle strength, muscle quantity/quality (skeletal muscle mass) and physical performance. Diagnosis of sarcopenia is confirmed by demonstrating reduced skeletal muscle mass while physical performance can be used to assess severity of sarcopenia. In past 5 years there are some studies indicating an association between treatment of lung cancer and decline in parameters of sarcopenia. Although remarkable improvements in medical treatments for non-small cell lung cancer (NSCLC) based on chemotherapy, targeted therapy and immunotherapy have been made, advanced lung cancer patients still have low five-year survival rate at 10-20 percent. Notably with a high prevalence of 43%, sarcopenia is shown to be a significant predictor of worsening overall survival and poor prognosis in NSCLC patients.
Cancer patients have expedited decline in skeletal muscle mass as compared to normal age-related decline in patients without cancer. Majority of older studies on NSCLC patients show that there is decrease in skeletal muscle mass during chemotherapy. Data on changes in skeletal muscles in NSCLC patients receiving targeted therapy and immunotherapy are limited, however studies suggest that patients experience decline in skeletal muscle mass while receiving these therapies as well. During treatment, in addition to decline in skeletal muscle mass, non-small cell lung cancer patients also exhibit decline in other parameters of sarcopenia i.e., muscle strength and physical performance as well. The impact of decline in parameters of sarcopenia leads to functional impairment with poor response to treatment, increased drug toxicities and poor quality of life. The value of measuring sequential decline in parameters of sarcopenia is not clearly understood. It is believed that interventions to treat sarcopenia can evolve if we can understand effects of different cancer therapies on sarcopenia. Early screening and treatment of sarcopenia in these patients may help to prevent functional impairment and improve overall survival.
Although there are other causes of sarcopenia in cancer patients such as impaired nutritional intake, low physical activity, causes relating to cancer therapies are not well established. There still remains a wide knowledge gap in understanding decline in different parameters of sarcopenia while patients are on different types of lung cancer treatment. Therefore, we aim to study a prospective cohort to evaluate differences in rate of decline in skeletal muscle mass and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/immunotherapy. The skeletal muscle mass and physical performance will be evaluated using computed tomography (CT) and short physical performance battery (SPPB) respectively. There is lack of validated cut-off values for CT-defined skeletal muscle mass in Thai population. Therefore, in Thai population, we aim to validate the cutoff values set by Japanese Society of Hepatology(JSH) based on recommendation of Asian Working Group for Sarcopenia (AWGS). As latest consensus on sarcopenia highlights importance of physical performance, if there exist an association between CT-defined skeletal muscle mass and physical performance, the former can be used in predicting physical functioning of patients. Therefore, we intend to determine baseline association between CT-defined skeletal muscle mass and physical performance as well. As far as we know there are no previous studies done to evaluate the differences in decline in skeletal muscle mass in patients who are unable to complete their first line chemotherapy and receive other line of chemotherapy (chemotherapy agents which are not considered first line), therefore we intent to study these differences too. Finally, this study also includes an evaluation of overall response rate of chemotherapy in patients with low CT-defined skeletal muscle mass.
This study is based in Songklanagarind Hospital and enrollment of participants will be as per our inclusion criteria which includes advanced lung cancer patients who are more than 18 years old treated with either chemotherapy, targeted therapy or immunotherapy. The sample size required for the study was estimated using simulation in Stata, with an estimated total N=240. According to treatment recommended by primary chest physician, participants will be divided into groups of chemotherapy (CMT) and targeted/immunotherapy (TKI/IO). Measurement of variables will take place in four different time period. Baseline characteristics will be measured before starting the treatment. The outcome variables our study i.e., computed tomography (CT)-defined skeletal muscle mass, short physical performance battery (physical performance) and health related quality of life using Thai Version of EQ-5D-5L Health Questionnaire (EQ-5D-5L) will be measured before starting treatment (T1), after 3rd, 6th and 9th months (T2, T3 and T4) of treatment. Additionally, after 3rd cycle of treatment "response evaluation criteria in solid tumors" (RECIST v1.1) will be recorded to evaluate response rate of chemotherapy. For patients who are unable to tolerate first line chemotherapy, they will be recruited for our 1st secondary objective and patients in this group will be evaluated only for CT-defined skeletal muscle mass in subsequent time period. At the end of our study, we will have three groups of patients i.e., patients receiving first line chemotherapy (CMT) patients on first line targeted/immunotherapy (TKI/IO) and patients on other line chemotherapy (OCMT).
Measuring skeletal muscle area (SMA) at L3 vertebral level using computed tomography scan is used to estimate total body skeletal muscle mass (SMM). Height adjusted SMA, also called skeletal muscle index (SMI) can be calculated by dividing SMA by patient's height square. As our study is based on Thai population, cut-off for diagnosis of CT-defined sarcopenia will be taken as L3 lumbar vertebra (L3SMI) \<42cm2/m2 for men and \<38 cm2/m2 for women. Short physical performance battery (SPPB) test will be used to evaluate physical performance. SPPB consists of set of three tests including balance test, gait test and 5 times chair stand test. Patients are asked to stand side-by-side, semi-tandem and tandem to measure balance. And then patients are asked to walk 4 meters to assess gait speed. Chair stand test is performed by asking the patient to fold their arms and stand up from seated position for five times. Points from 0 to 12 will be given according to time required to perform above tests. Health related quality of life will be measured using the Thai Version of EQ-5D-5L Health Questionnaire. This is validated tool for use in Thailand which has a self-completed questionnaire for adults consisting of 5 dimensions of mobility, self-care, usual activities, pain/discomfort and anxiety/depression The baseline characteristics will be presented with n (%) and mean (SD) or median (IQI) as appropriate. Chi-square test (or Fisher Exact test), Student t-test (or Kruskal-Wallis test) will be calculated to evaluate the differences of baseline data between CMT and TKI/IO groups. The baseline correlation between SPPB and SMI will be presented with scatter plot and LOWESS line. The change of SMI after 6th cycles of treatments and the differences of the change between CMT and TKI/IO groups will be calculated using Student t-test or Kruskal-Wallis test. Multivariable linear regression will be used to adjust the imbalance of baseline characteristics between these two-groups. Decline in SMI for CMT and OCMT will be calculated using same analysis. The rate of decline in SMI (and SPPB score) will be calculated using multilevel-linear regression (Mixed linear regression) and will be shown in two-way graph. The response rate to chemotherapy will be analyzed using logistic regression. The p-value of less the 0.05 will be considered statistically significant. The analysis and graphically figures will be shown using Stata/MP 17.0, StataCorp, 4905 Lakeway Dr, College Station, TX 77845, USA.
Stage III and IIIC (if patients are treated with TKI/IO), and Stage IV non-small cell lung cancer patients who are receiving chemotherapy or targeted therapy/immunotherapy (TKI/IO) treated in Songklanagarind Hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Chemotherapy drug
Drug: Targeted Agent · Drug: Immunotherapy
Chemotherapy drug as prescribed by primary treating physician
Targeted agents as prescribed by primary treating physician
Immunotherapy as prescribed by primary treating physician
To determine the differences in the rate of decline in CT defined skeletal muscle index at L3 vertebra and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/ immunotherapy, before and after treatment.
To determine the differences in the rate of decline in CT defined skeletal muscle index at L3 vertebra and physical performance in advanced NSCLC patients receiving chemotherapy and targeted therapy/ immunotherapy, before and after treatment.
Time frame: 1 year
To determine validity of gender based cut off for CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) based on recommendation of JSH/AWGS in Thai population.
1. To determine validity of gender based cut off for CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) based on recommendation of JSH/AWGS in Thai population.
Time frame: 1 year
2. To determine baseline association between CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) and physical performance using SPPB in advanced NSCLC patients.
2. To determine baseline association between CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) and physical performance using SPPB in advanced NSCLC patients.
Time frame: 1 year
4. To determine differences in rate decline in skeletal muscle mass using CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) in patients receiving first line chemotherapy (CMT) and other line chemotherapy (OCMT).
4. To determine differences in rate decline in skeletal muscle mass using CT-defined skeletal muscle index at L3 lumbar vertebra (L3SMI) in patients receiving first line chemotherapy (CMT) and other line chemotherapy (OCMT).
Time frame: 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2022 (actual). Primary completion is estimated for Aug 2024, 24 months after the start.
Of 192 non-industry observational studies under Sarcopenia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 63. This study's planned 24 months is close to that.
Counting every sponsor, half of 194 studies reached it within 26 months; a quarter within 12 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Prince of Songkla University →